期刊文献+

利拉鲁肽对2型糖尿病大鼠NF-κB及VCAM-1表达的影响 被引量:7

Effect of liraglutide on the expressions of NF-κB and VCAM-1 in aorta endothelium of type 2 diabetic rats
原文传递
导出
摘要 目的观察利拉鲁肽对2型糖尿病大鼠主动脉核因子-κB(NF-κB)及血管细胞间黏附因子(VCAM-1)表达的影响及可能机制。方法高脂高糖饲料喂养联合小剂量链脲佐菌素腹腔注射,建立2型糖尿病大鼠模型。40只8周龄雄性SD大鼠分为4组:正常对照组(NC组)、糖尿病对照组(DM组)、格列本脲对照组(DMG组)及利拉鲁肽干预治疗组(DML组)。DMG组及DML组分别给予格列本脲及利拉鲁肽干预治疗8周。12周末腹主动脉取血分离血清,测空腹血糖(FBG)、空腹胰岛素(FIns)、甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C);分离大鼠主动脉,石蜡切片HE染色观察大鼠主动脉形态学变化;免疫组化方法(SP法)测大鼠主动脉NF-κB及VCAM-1的表达。结果与DM组相比,DMG组及DML组大鼠FIns及胰岛素抵抗指数(HOMA-IR)明显降低(P均<0.01);与DMG组相比,DML组大鼠FIns、HOMA-IR、TG及LDL-C明显降低(P均<0.05),主动脉NF-κB和VCAM-1的表达降低(P<0.05)。结论利拉鲁肽可下调糖尿病大鼠主动脉NF-κB和VCAM-1的表达,调节糖脂代谢。此过程可改善大血管并发症。 Objective To investigate the effect of liraglutide on the expressions of nuclear factor-kappa B ( NF-κB) and vascular cell adhesion molecule 1 (VCAM-1) in aorta endothelium of type 2 diabetic rats and the possible mechanism. Methods Forty male SD rats were divided into the normal control group (NC group), diabetic control group (DM group), glibenclamide group (DMG group) and liraglutide group (DML group).The model of type2 diabetic rats was eatablised by injecting with low-dose streptozocin( STZ) into abdominal cavity of SD rats after high-fat and high-sugar diet.Then rats in DMG and DML groups were treated with liraglutide and glibenclamide for 8 weeks.At the end of the twelfth week, blood was taken from abdominal aorta to examine biochemical indexes including fasting blood-glucose (FBG), fasting insulin(FIns), totalcholesterol(TC), triglyceride(TG), low density lipoprotein-cholesterol(LDL-C) and high density lipoprotein-cholesterol ( HDL-C) .The thoracic aorta was isolated to observe the histological parame-ters by HE staining.The expressions of NF-κB and VCAM-1 in aorta endothelium were determined by immunohisto-chemical method.Rusults The levels of FIns and HOMA-IR in DMG group and DML group were decreased com-pared with those in DM group (P&lt;0.01).The levels of FIns, HOMA-IR,TG and LDL-C and the expressions of NF-κB and VCAM-1 in in aorta endothelium in DML group were decreased compared with those in DMG group ( P&lt;0.05).Conclusion Liraglutide can decrease the expressions of NF-κB and VCAM-1 in aorta endothelium of type2 di-abetic rats and improve glucolipid metabolism.This may be involved in vascular complications of diabetes.
出处 《山东大学学报(医学版)》 CAS 北大核心 2014年第4期39-42,48,共5页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金(30660070) 山东省优秀中青年科学家科研奖励基金(BS2010YY002)
关键词 利拉鲁肽 糖尿病大鼠 血管细胞间黏附因子1 VASCULAR cell adhesion MOLECULE 1 核因子-κB Liraglutide Diabetic rats Nuclear factor-kappa B
  • 相关文献

参考文献15

  • 1Scheen A J.Glueagon-like peptide-1(GLP-1),a new tar-get for the treatment of type 2 diabetes [J].Rev Med Liege,2007,62(4):217-221. 被引量:1
  • 2De Ore K,Greig N H,Holloway H W,et al.The effects of GLP-I on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test[J].Gerontol A Biol Sci Med Sci,1997,52(5):B245-249. 被引量:1
  • 3Raun K,von Voss P,Gotfredsen C F,et al.Liraglutide,a long-acting glucagon like peptide-1 analog,reduces body weight and food intake in obese candy fed rats,whereas a dipeptidyl peptidase-4 inhibitor,vildagliptin,does not [J].Diabetes,2007,56(1):8-15. 被引量:1
  • 4Imamura S,Hirai K,Hirai A.The glucagon-like peptide-1 receptor agonist,liraglutide,attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients [J].Tohoku J Exp Med,2013,231(1):57451. 被引量:1
  • 5Kim Chung le T,Hosaka T,Yoshida M,et al.Exendin-4,a GLP-I receptor agonist,directly induces adipone-ctinexpression through protein kinase A pathway and pre-vents inflammatory adipokine expression [J].Biochem Biophys Res Commun,2009,390(3):613-618. 被引量:1
  • 6Nystrtim T,Gutniak M K,Zhang Q,et al.Effects of glucagon-like peptide-I on endothelial function in type 2 diabetes patients with stable coronary artery disease [J].Am J Physiol Endocrinol Metab,2004,287(6):E1209-1215. 被引量:1
  • 7Gaspari T,Welungoda I,Widdop R E,et al.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis,plaque stability and endothelial function in an ApoE(-/-)mouse model[J].Diab Vasc Dis Res,2013,10(4):353-360. 被引量:1
  • 8Hu Y,Liu H,Simpson R W,et al.GLP-l-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells[J].Mol Biol Rep,2013,40(3):2273-2279. 被引量:1
  • 9郭啸华,刘志红,李恒,黎磊石.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志,2002,10(5):290-294. 被引量:304
  • 10Martin-Ventura J L,Blanco-Colio L M,Mufioz-Garcia,et al.NF-kappaB activation and Fas ligand overexpres-sion in blood and plaques of patients with carotid athero-sclerosis:potential implication in plaque instability [J].Stroke,2004,35(2):458-463. 被引量:1

二级参考文献21

  • 1高虹,宁光.胰高血糖素样肽1的胰腺外作用研究进展[J].国际内科学杂志,2007,34(7):408-411. 被引量:25
  • 2Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a longacting human glueagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care, 2007,30 : 1608-1610. 被引量:1
  • 3Chia CW, Egan JW. Ineretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab, 2008,93 : 3703-3716. 被引量:1
  • 4Nystrom T,Gutniak MK, Zhang Q, et al. Effects of glucagonlike peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab, 2004,287 : E1209-E1215. 被引量:1
  • 5Ozyazgan S,Kutluata N,Afsar S,et al. Effect of glucagonklike peptide-1(7-36) and exendin-4 on vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology, 2005,74:119-126. 被引量:1
  • 6Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA, 2005,293 : 830-835. 被引量:1
  • 7Naftanel MA, Harlan DM. Pancreatic islet transplantation. Plos Med,2004,1 :e58-e75. 被引量:1
  • 8Yonekawa Y, Matsumoto S, Okitsu T, et al. Effective islet isolation method with extremely high islet yields from adult pigs. Cell Transplant, 2005,14: 757-762. 被引量:1
  • 9Elhadd TA, Kennedy G, Robb R, et al. Elevated soluble cell adhesion molecules E-selectin and intercellular cell adhesion molecule-1 in type-2 diabetic patients with and without asymptomatic peripheral arterial disease. Int Angiol, 2004,23 :128-133. 被引量:1
  • 10Yu BS,Wang AR. Glucagon like peptide l based therapy for type 2 diabetes. World J Pediatr, 2008,4 : 8-13. 被引量:1

共引文献306

同被引文献62

引证文献7

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部